USSTOCK.TODAY
Regular Market
Log in Sign up

Palatin Technologies Prepares for Next-Generation Peptide Clinical Trials

FinanceWire · ·by G4L

PTN
PTN Palatin Technologies Inc
$7.23 +15.31%
View chart & analysis →
GILD +1.46% NVO +2.65%RYTM RYTM +1.48%
  1. 1Palatin Technologies is preparing for the first human trials of its next-generation peptide in 2027.
  2. 2In obesity-related clinical studies conducted in 2025, 40% of the group receiving combined doses of bremelanotide and tirzepatide achieved at least 5% weight loss.
  3. 3Palatin Technologies CEO Karl Spagnolo said that MC4R agonists have been clinically and commercially validated.

So what's the key point?

Palatin Technologies is preparing to test a new drug in humans in 2027. In obesity-related research, 40% of participants showed results in losing weight.

Source FinanceWire · View original ↗

Related 3-line summaries

Gilead Sciences shares hit all-time high The Motley Fool +1 · 7h agoNovonesis targets supplement market to support GLP-1 users CNBC · yesterdayEli Lilly widens market cap gap with Novo Nordisk in obesity treatment competition The Motley Fool +7 · yesterday
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news